← All trials
NCT02219880
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 13, 2015
- Primary completion
- May 31, 2018
- Completion date
- May 31, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 210
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of MelbourneLead sponsor
- University of MelbourneOverall official - principal investigator
- University of MelbourneReponsible party - principal investigator
- Swinburne UniversityCollaborator
- University of QueenslandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.